October 6, 2017
New vice president for Sobi
Swedish Orphan Biovitrum AB (publ) (Sobi) has appointed Norbert Oppitz as Senior Vice President for the newly established business area Specialty Care.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
October 5, 2017
Tigenix to present positive Chron’s disease treatment testing results in Florida, USA
TiGenix NV has achieved positive results from its ADMIRE-CD Phase III clinical trial of Cx601 for the treatment of complex perianal…
October 4, 2017
FDA simplifies Institutional Review Board review requirements for physicians seeking patient expanded access
FDA has announced updates to three final guidances, including Form FDA 3926 and its instructions, to simplify Institutional Review Board (IRB)…
October 4, 2017
Timing of oral dosing relative to meals drove the lower than expected drug exposures
Data presented by Tetraphase Pharmaceuticals at IDWeek confirmed that the timing of oral dosing relative to meals drove the lower…
October 4, 2017
Gilead, MPP: single-tablet regimen has potential to simplify the management of HIV
The Medicines Patent Pool (MPP) today announced a licence with Gilead Sciences for bictegravir (BIC), now under review in the United…
October 4, 2017
OptiBiotix Health launches SlimBiome and LPLDL
OptiBiotix Health has kicked off with its SlimBiome and LPLDL products at Supply Side West in Las Vegas, in late September 2017.
October 4, 2017
Evgen Pharma gets first European manufacturing patent
Evgen Pharma got the grant of the first European patent for its lead product, SFX-01.
October 4, 2017
ImmuPharma, Lanstead Capital finish sharing deal, Phase III results for Lupuzor in Q1 2018
ImmuPharma has completed a sharing agreement with Lanstead Capital from February 2016, for supporting of ImmuPharma’s pivotal Phase III clinical trial…
October 3, 2017
FDA accepts sNDA filing for Allergan’s pneumonia drug
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Allergan’s Avycaz (ceftazidime and avibactam) for priority review.
October 3, 2017
Sanofi appoints new EVP Diabetes & Cardiovascular
Sanofi has appointed Stefan Oelrich as Executive Vice President Diabetes & Cardiovascular (DCV), effectively immediately.